Cargando…

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104

Activation of prodrugs in tumors (e.g., by bioreduction in hypoxic zones) has the potential to generate active metabolites that can diffuse within the tumor microenvironment. Such “bystander effects” may offset spatial heterogeneity in prodrug activation but the relative importance of this effect is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foehrenbacher, Annika, Patel, Kashyap, Abbattista, Maria R., Guise, Chris P., Secomb, Timothy W., Wilson, William R., Hicks, Kevin O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791487/ https://www.ncbi.nlm.nih.gov/pubmed/24109591 http://dx.doi.org/10.3389/fonc.2013.00263

Ejemplares similares

Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling
por: Foehrenbacher, Annika, et al.
Publicado: (2013)

Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures
por: Hong, Cho R., et al.
Publicado: (2018)

Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104
por: Benito, Juliana, et al.
Publicado: (2011)

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients
por: McKeage, Mark J, et al.
Publicado: (2011)

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3
por: Abbattista, Maria R., et al.
Publicado: (2021)

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect()()
por: Hong, Cho Rong, et al.
Publicado: (2018)

Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling
por: Jackson-Patel, Victoria, et al.
Publicado: (2022)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021)

The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach
por: Ball, Patrick, et al.
Publicado: (2023)

DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104A
por: Stornetta, Alessia, et al.
Publicado: (2017)

Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy
por: Dachs, Gabi U., et al.
Publicado: (2009)

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours
por: McKeage, Mark J, et al.
Publicado: (2012)

Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models
por: Stokes, Ashley M., et al.
Publicado: (2016)

Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A
por: Erzinger, Melanie M., et al.
Publicado: (2016)

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
por: Dickson, Benjamin D., et al.
Publicado: (2019)

Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
por: Hunter, Francis W, et al.
Publicado: (2016)

Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug
por: Cheng, T L, et al.
Publicado: (1999)

Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications
por: Ashoorzadeh, Amir, et al.
Publicado: (2022)

An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids
por: Mao, Xinjian, et al.
Publicado: (2018)

Hypoxia-activated prodrugs and redox-responsive nanocarriers
por: Zeng, Yun, et al.
Publicado: (2018)

Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy
por: Denny, William A.
Publicado: (2022)

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
por: Guise, Christopher P., et al.
Publicado: (2014)

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials
por: Spiegelberg, Linda, et al.
Publicado: (2019)

The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

In vitro radiosensitization of breast cancer with hypoxia‐activated prodrugs
por: Aiyappa‐Maudsley, Radhika, et al.
Publicado: (2022)

Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug
por: Rais, Rana, et al.
Publicado: (2022)

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
por: Phillips, Roger M.
Publicado: (2016)

Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma
por: Liu, Shujing, et al.
Publicado: (2017)

The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
por: Nytko, Katarzyna J., et al.
Publicado: (2017)

Hypoxia-Activated Albumin-Binding Exatecan Prodrug for Cancer Therapy
por: Cheng, Zhiyang, et al.
Publicado: (2021)

Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents
por: Omran, Ziad, et al.
Publicado: (2021)

Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302
por: Wojtkowiak, Jonathan W, et al.
Publicado: (2015)

Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors
por: Lindsay, Danika, et al.
Publicado: (2016)

Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer
por: Shah, Vidhi M., et al.
Publicado: (2022)

Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors
por: Hay, Michael P., et al.
Publicado: (2019)

From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates
por: Wang, Yanming, et al.
Publicado: (2022)

Significance of Specific Oxidoreductases in the Design of Hypoxia-Activated Prodrugs and Fluorescent Turn off–on Probes for Hypoxia Imaging
por: Janczy-Cempa, Ewelina, et al.
Publicado: (2022)

Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302
por: Lohse, Ines, et al.
Publicado: (2016)

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
por: Meng, Fanying, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_umr2el3cr5eis53r04es86jvt7